UBS Group
MDGL icon

UBS Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

UBS Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-571
Closed -$7K – 7952
2015
Q4 		$7K Hold
571
– – ﹤0.01% 7517
2015
Q3 		$35K Hold
571
– – ﹤0.01% 6148
2015
Q2 		$45K Buy
571
+57
+11% +$4.78K ﹤0.01% 6087
2015
Q1 		$35K Hold
514
– – ﹤0.01% 6390
2014
Q4 		$48K Buy
+514
New +$53.1K ﹤0.01% 6527

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's MDGL Position: Q1 2026 in Review

UBS Group increased its Madrigal Pharmaceuticals (MDGL) stake by 15% in Q1 2026, buying an estimated $7.23M and bringing the position to 117,779 shares worth $61.7M. The position accounts for 0.01% of the portfolio, ranked #1433.

UBS Group first reported a position in MDGL in Q4 2014 and has held it in 45 quarters since. The position peaked at $153M in Q2 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • UBS Group held 117,779 shares of Madrigal Pharmaceuticals worth $61.7M as of Q1 2026.
  • UBS Group bought 15,138 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $7.23M.
  • Madrigal Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1433 holding.
  • UBS Group first reported a position in Madrigal Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
  • UBS Group's Madrigal Pharmaceuticals position peaked at $153M in Q2 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.